Coming 2019

Day One
Wednesday April 25, 2018

Day Two
Thursday April 26, 2018

08.00
Registration & Breakfast

Dynamics of Underlying Causes & Current Understandings of Autoimmunity

09.00
Chair’s Opening Remarks

  • Arpita Maiti Senior Director, External Science & Innovation, Inflammation, Immunology and Microbiome, Pfizer

09.10
The Underlying Causes of Autoimmunity: How to Develop Broader Immune Modulation Models?

  • Lawrence Steinman Professor at Stanford University & Executive Chairman of the Board, Tolerion

Synopsis

  • How to leverage our current understanding of causes of autoimmune diseases
  • Explore emerging science & technologies towards overcoming autoimmunity

09.35
Accessing Innovation in Antigen-Specific Immune Tolerance – A Big Pharma View

  • Arpita Maiti Senior Director, External Science & Innovation, Inflammation, Immunology and Microbiome, Pfizer

Synopsis

  • Antigen-specific immune tolerance will form the basis of future transformative therapies for autoimmune diseases that have the potential to be curative
  • Approaches/modalities to induce immune tolerance are complex and will require innovation across the drug development and commercialization pathway
  • Big pharma deploys multiple vehicles to access this innovation and augmenting it with in-house capabilities to bring new medicines to patients in need

10.00
Overview of NIAID- Sponsored Research on Antigen-Specific Immune Tolerance

  • Daniel Rotrosen Director, Division of Allergy, Immunology & Transplantation, NIAID/NIH

Synopsis

  • Successful tolerance induction will require multifaceted approaches tailored to specific diseases and patient populations
  • Partnerships spanning the pharmaceutical industry, non-profits, and governmental entities will be important in achieving this goal

10.25
Speed Networking & Morning Refreshments

Analyzing the Scope & Strategies to Antigen-Specific Immune Tolerance

11.00
Challenges and Opportunities to Develop Immune Tolerance Approaches to Cure Type 1 Diabetes

Synopsis

  • Immune tolerance has game changing potential for Type 1 Diabetes
  • Exploratory biomarkers and digital health could accelerate clinical development in Type 1 Diabetes
  • Combinations of immune tolerance and regenerative approaches might be required to treat entire patient population (e.g. also cases of long lasting disease)

11.25
The Potential of Antigen-Specific Therapies as Part of a Combination Approach to Type 1 Diabetes Therapy

Synopsis

  • Type 1 Diabetes is both a beta cell and immune driven disease
  • Combination therapies will be required to achieve significant therapeutic benefit
  • Role of disease specific foundations in driving progress

11.50
The Potential of B Cell Tolerance in Autoimmunity

Synopsis

  • Distinctions between B and T cell Tolerance
  • Potential for Establishing Tolerance
  • Do we need B cell Tolerance?

12.15
Networking Lunch

Identification, Validation & Targeting of Specific Antigens for Immune Tolerance Therapies

13.15
Case Study: Key Lessons Learned from Regulatory T Cells for Cellular Therapy

Synopsis

  • Human Tregs are comprised of functionally distinct subsets
  • Lack of suppression can be due to Treg resistance
  • Xenogeneic GVHD to examine human Treg cellular therapies

13.40
Case Study: Efficient Intracellular Microfluidic Delivery into RBCs to Induce Tolerance

  • Finola Moore Project Leader & Senior Scientist, SQZ Biotech

Synopsis

  • SQZ delivers antigen efficiently into RBCs
  • SQZ’s RBCs are cleared from circulation in a tolerogenic manner
  • SQZ’s RBCs prevent CD4 and CD8 response to model antigen Ova as well as disease
    models

14.05
Afternoon Refreshments & Networking

14.35
Case Study: Generation of Antigen-Specific Immune Tolerance by Harnessing the Liver’s Natural Capabilities

Synopsis

  • The liver as a tolerogenic organ
  • Accessing selected liver functionalities by nanoparticles
  • Development requirements for nanomedicine

15.00
Case Study: From Bench to Bedside: An Antigen-Encapsulating Nanoparticle-based Negative T Cell Vaccine for Tolerogenic Therapy of Autoimmune Disease

  • Stephen Miller Professor at Northwestern University Medical School & Co-founder, Cour Pharmaceutical

Synopsis

  • Tolerance induction using antigen-encapsulating PLG nanoparticles recapitulates how self tolerance is maintained in the hematopoietic system
  • Tolerance is exquisitely antigen-specific and depends on targeting tolerogenic APCs in the spleen and liver
  • Tolerance induction and long-term maintenance is dependent on antigen-specific Tregs

Improving the Pre-Clinical Predictability of Antigen-Specific Immune Tolerance Therapies

15.25
Case Study: NKTR-358: A Selective Regulatory T Cell Inducing Agent for the Treatment of Autoimmune and Inflammatory Diseases

Synopsis

  • Regulatory T cells numbers and suppressive function are elevated following administration of NKTR-358
  • NKTR-358 is selective for regulatory T cells with a wide margin of activity between regulatory vs conventional T cells
  • NKTR-358 delivers efficacy in multiple preclinical models, generating long-lasting antigen-specific regulatory T cell responses

15.50
Case Study: Induction of Autoantigen-Specific Regulatory T Cells In Vivo to Treat Autoimmunity

  • Wanjun Chen Senior Investigator (prof.) and Chief, NIDCR/NIH

Synopsis

  • How to induce autoantigen-specific regulatory T cells in the animals without compromising the overall immunity especially the anti-infection and anti-tumor immunity?
  • Will show our success in animal models of autoimmunity, and hopefully to seek possibility and collaborations to translate these findings to human patients to do real precision medicine with purpose to treat/cure autoimmune diseases”

16.15
Pannel Discussion: Pre-Clinical Proof of Concept In Vivo: Realistic or a Dream?

  • Finola Moore Project Leader & Senior Scientist, SQZ Biotech
  • Todd Zion President & CEO, Akston Biosciences
  • Francisco J. Quintana Associate Professor at Harvard; Co Founder & Director, AnTolRx
  • Lachy McLean VP, Head of Clinical & Translational Sciences, Immunology, Takeda Pharmaceuticals

Synopsis

  • What experimental models are available to test tolerogenic approaches?
  • Which readouts can be used to predict efficacy in human studies?
  • Can pre-clinical models identify readouts for proof of mechanism studies?

17.00
Chair’s Closing Remarks & End of Day One

  • Arpita Maiti Senior Director, External Science & Innovation, Inflammation, Immunology and Microbiome, Pfizer